StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of Trevena stock opened at $1.13 on Friday. The stock’s fifty day moving average is $1.49 and its 200 day moving average is $1.78. Trevena has a one year low of $0.95 and a one year high of $11.25. The stock has a market cap of $976,320.00, a P/E ratio of -0.02 and a beta of 1.10.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.